DNA vaccination against neu reduces breast cancer incidence and metastasis in mice

Cancer Gene Therapy

Volumn 8, Issue 4, 2001, Pages 259-268

  Lachman, Lawrence B ^a   Rao, Xiao Mei ^a   Kremer, Ronald H ^a   Ozpolat, Bulent ^a   Kiriakova, Galina ^a   Price, Janet E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antitumor; ErbB 2; Gene vaccine

Indexed keywords

DNA VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; INCIDENCE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; TARGET CELL; TUMOR GROWTH; VACCINATION; VIRUS REPLICATION;

ANIMALS; FEMALE; FLOW CYTOMETRY; INCIDENCE; INTERFERON TYPE II; INTERLEUKIN-4; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PRECIPITIN TESTS; RECEPTOR, ERBB-2; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINATION; VACCINES, DNA;

ANIMALIA; MURINAE; MUS MUSCULUS; SINDBIS VIRUS;

EID: 0035021053     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700300     Document Type: Article

References (20)

1. Fornier M, Munster P, Seidman AD. Update on the management of advanced breast cancer. Oncology. 1999;13:647-658.
2. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5:1289-1297.
3. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9:125-138.
4. Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol. 1999;26:41-50.
5. Conry RM, LoBuglio AF, Curiel DT. Polynucleotide-mediated immunization therapy of cancer. Semin Oncol. 1996;23:135-147.
6. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000;18:927-974.
7. Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 2000;60:51-55.
8. Dubensky TW Jr, Polo JM, Liu MA. Live virus vaccines: something old, something new, something borrowed. Nat Med. 1998;4:1357-1358.
9. Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000;19:142-153.
10. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Nad Acad Sci USA. 1992;89:10578-10582.
11. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis. 1983;3:22-31.
12. Mukhopadhyay R, Theriault RL, Price JE. Increased levels of 6 integrins are associated with the malignant phenotype of human breast cancer cells. Clin Exp Metastasis. 1999;17:325-332.
13. Hariharan MJ, Driver DA, Townsend K, et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol. 1998;72:950-958.
14. Muller WJ, Sinn E, Pattengale PIC, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988;54:105-115.
15. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med. 2000;191:1699-1708.
16. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/ macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355-366.
17. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465-1468.
18. Chattergoon M, Boyer J, Weiner DB. Genetic immunization - a new era in vaccine and immune therapeutics. FASEB J. 1997;11:753-763.
19. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full-length or truncated neu induce protective immunity against new-expressing mammary tumors. Cancer Res. 1998;58:1965-1971.
20. Amici A, Smorlesi A, Noce G, et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 2000;7:703-706.